Column
- HOME
- Column
You can view the research column published every month by SMC Laboratories.
2025.02.02
Comparison data between NASH-HCC patients and our NASH-HCC model
We have acquired the gene expression data (RNA-seq data) using our STAMTM model. Additionally, we have compared the gene expression data between the STAMTM model and NASH-HCC patients. As a result, we found that many of the gene expression changes were common in both the STAMTM model mice and NASH-HCC patients as well as…
2025.02.02
Drug Efficacy Studies in NASH Mouse Model
Today, we would like to introduce a study published by our client, Tsumura, in which they used our pre-clinical services (Ishizawa et al., Gene. 2022) to test their compound in our proprietary NASH model called STAMTM. To give you a little background on this model, the STAMTM mice have a diabetic background and follow…
2025.02.02
In-vivo screening and pharmacology study for liver cancer
We would like to introduce an in-vivo screening study using our liver orthotopic xenograft and STAM™ models. In case you are unfamiliar with these models, we would like to quickly present them, which could be extremely useful to you. ■ STAM™ The STAM™ was developed by SMC Laboratories as the world’s first mouse model…
2025.02.02
Pre-clinical studies for Liver Cancer: STAM model
For Today’s topic, I would like to focus on Hepatocellular Carcinoma (HCC). We have summarized the characteristics of the various liver cancer models, and you can learn more about them by clicking on the link below. If you are interested in learning about how to prevent and treat liver cancer, please read on. …
2025.02.02
Characterization of a lung fibrosis model and its usefulness
We offer the Idiopathic Pulmonary Fibrosis (IPF) model as a potential model for the development of therapeutics for lung fibrosis, and many of our customers have used this model through our introduction of its usefulness. What is Bleomycin-Induced model for Idiopathic Pulmonary Fibrosis? Bleomycin is a chemotherapeutic agent used to treat cancer, but…
2025.02.02
Interesting relevance between liver cancer patients and our cancer mouse model
Do you have any interest in liver cancer, hepatocellular carcinoma (HCC), or doing research about HCC? We hope the relevant information between HCC and the STAMTM model will be useful to you. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, the fifth most frequent form of cancer, and the third…
2025.02.02
STAM mice develop NASH-derived hepatocarcinoma
Last year, the following article was even published in Nature Reviews Gastroenterology & Hepatology. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention –What is liver cancer? Liver cancer is the sixth most common cancer in the world and the third most common cause of cancer-related death in 2020. Among them, hepatocellular carcinoma…
2025.02.02
Combination Therapies for NASH
It is now accepted that many factors are involved in exacerbating the NASH pathophysiology such as lipotoxicity, oxidative stress, microbiome and immune cell mechanisms. To date, numerous molecules with different mechanisms of action have been developed to treat NASH, although reported efficacy to date has been limited. Considering the complexity of the pathophysiology, many companies…
2025.02.02
Pre-clinical studies for NASH: CDAHFD mice model
Today, we would like to give you a brief introduction to the choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD)-induced NASH model. The CDAHFD model is a non-obese NASH model that is induced by feeding the test animals a choline-deficient, L-amino acid-defined, high-fat diet. The model reproduces NASH phenotypes such as marked steatosis, immune cell infiltration and…
2025.02.02
Case study of preclinical studies for NASH
Among our lineup is the STAM™ model, which is our proprietary model that shows a 100% progression rate from NASH-HCC. This model also boasts a high clinical correlation and has been featured in over 70 papers and more than 80 presentation. What is more, over 10 of our clients that have used this model have…
We can help you advance your research.